Correction to “GSK3β inhibitor TDZD8 ameliorates brain damage through both ROS scavenging and inhibition of apoptosis in hyperglycemic subarachnoid haemorrhage rats”

IF 2.9 4区医学 Q2 Medicine

Clinical and Experimental Pharmacology and Physiology Pub Date : 2024-04-18 DOI:10.1111/1440-1681.13853

引用次数: 0

Abstract

Citation to article being corrected.

None.

Error description of text.

In Figure 5A, Section of Results, the group SAH + STZ was incorrectly combined as an error, caused by our unconscious saving mistake when taking too many florescence pictures.

We apologize for this error.

Error description of figure.

We apologize for this error.

Abstract Image

查看原文本刊更多论文

对 "GSK3β抑制剂TDZD8通过清除高血糖蛛网膜下腔出血大鼠体内的ROS和抑制细胞凋亡改善脑损伤 "的更正

在图 5A 的结果部分，SAH + STZ 组被错误地合并为一个错误，这是由于我们在拍摄过多荧光图片时无意识的保存错误造成的，我们对此错误深表歉意。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Experimental Pharmacology and Physiology 医学-生理学

CiteScore

6.20

自引率

0.00%

发文量

128

审稿时长

6 months

期刊介绍： Clinical and Experimental Pharmacology and Physiology is an international journal founded in 1974 by Mike Rand, Austin Doyle, John Coghlan and Paul Korner. Our focus is new frontiers in physiology and pharmacology, emphasizing the translation of basic research to clinical practice. We publish original articles, invited reviews and our exciting, cutting-edge Frontiers-in-Research series’.